[go: up one dir, main page]

Gully et al., 1995 - Google Patents

Neuropharmacological profile of non‐peptide neurotensin antagonists

Gully et al., 1995

Document ID
9786758527752936739
Author
Gully D
Jeanjean F
Poncelet M
Steinberg R
Soubrie P
Fur G
Maffrand J
Publication year
Publication venue
Fundamental & clinical pharmacology

External Links

Snippet

Neurotensin, an endogenous peptide widely distributed throughout the brain, fulfils neurotransmitter criteria. When administered centrally, neurotensin induces various effects and modulates the activity of the mesolimbic dopamine system. It antagonizes the …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Similar Documents

Publication Publication Date Title
Bonaventura et al. Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability
Allison et al. Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence
Fitzgerald et al. Prolactin and dopamine: what is the connection? A review article
Sugimoto et al. Evidence for the involvement of GABAA receptor blockade in convulsions induced by cephalosporins
Kleczkowska et al. Neurotensin and neurotensin receptors: Characteristic, structure–activity relationship and pain modulation—A review
Dunah et al. Regional and ontogenic expression of the NMDA receptor subunit NR2D protein in rat brain using a subunit‐specific antibody
Tian et al. Bidirectional modulatory effect of orphanin FQ on morphine-induced analgesia: antagonism in brain and potentiation in spinal cord of the rat
Blakely et al. Biogenic amine neurotransmitter transporters: just when you thought you knew them
Panula et al. Neuropeptide FF and modulation of pain
Webb et al. Molecular pharmacology of the glycine receptor chloride channel
Sanna et al. Differential subunit dependence of the actions of the general anesthetics alphaxalone and etomidate at γ-aminobutyric acid type A receptors expressed in Xenopus laevis oocytes
Buck et al. Neuroadaptive responses to chronic ethanol
Breitinger et al. Modulators of the inhibitory glycine receptor
Gully et al. Neuropharmacological profile of non‐peptide neurotensin antagonists
US11351264B2 (en) PAR2 mimetic peptides and uses thereof
Carlberg et al. Autoradiographic Localization of Cholecystokinin A and B Receptors in Rat Brain Using [125I] D‐Tyr25 (NIe28, 31)‐CCK 25‐33S
Gibbs et al. Structure, function and physiology of 5-hydroxytryptamine receptors subtype 3
Martin et al. GABA receptors
Lahti et al. Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia
Ibi Role of interaction of mGlu2 and 5-HT2A receptors in antipsychotic effects
Cinar et al. Reciprocal inhibition of G-protein signaling is induced by CB1 cannabinoid and GABAB receptor interactions in rat hippocampal membranes
Antoniou et al. Differential effects of the neuropeptide galanin on striatal acetylcholine release in anaesthetized and awake rats
Boules et al. Neurotensin agonists as an alternative to antipsychotics
Bentué-Ferrer et al. 5-HT-moduline, a 5-HT1B/1D receptor endogenous modulator, interacts with dopamine release measured in vivo by microdialysis
Cuello et al. Pharmacological Sciences: Perspectives for Research and Therapy in the Late 1990s: Perspectives for Research and Therapy in the Late 1990s